Daniel J. Lippis has sold EW and made no open-market buys since Mar 2024

Daniel J. Lippis is a corporate vice president and general manager of Transcatheter Aortic Valve Replacement (TAVR) at Edwards Lifesciences Corp, a global leader in structural heart disease therapies.( He has been with Edwards Lifesciences since 2010 and has held multiple leadership roles across the U.S., Europe, and Asia Pacific, including serving as senior vice president of Europe THV, where he led sustained growth of TAVR technology in a mature market and developed a high-touch commercial model.( As CVP, TAVR, he oversees the company’s global TAVR portfolio and division strategy, building on years of experience that include previously running Edwards’ TAVR division in Europe.(

Lippis is a career medical device executive with more than 25 years of experience in the medtech industry, including prior leadership roles at Johnson & Johnson.( His expertise spans general management, sales and marketing leadership, strategy, R&D and portfolio planning, brand management, professional education, medical affairs, regulatory affairs, finance, and human resources.( He holds a Bachelor of Science from the University of Adelaide and a Master’s degree in Marketing from the University of Technology Sydney.( As a corporate insider at Edwards Lifesciences, Lippis has reported multiple equity transactions under Rule 10b5-1 trading plans and currently holds tens of thousands of shares and employee stock options in the company, underscoring his long-term alignment with Edwards’ TAVR business.(

Written by Perplexity from public sources.